Omalizumab
證據等級: L2 | 預測適應症: 10 個
## 藥師評估報告
Omalizumab：從 過敏性氣喘 到 支氣管炎與異位性皮膚炎
一句話總結
Omalizumab（喜瑞樂）是一種抗 IgE 單株抗體，用於治療重度過敏性氣喘和慢性蕁麻疹。TxGNN 模型預測它對**支氣管炎 (bronchitis)** 和**異位性皮膚炎 (atopic eczema)** 有潛在治療效果，目前有多項臨床試驗和文獻支持這些預測。
快速總覽
| 項目 | 內容 |
|---|---|
| 原適應症 | 重度過敏性氣喘、慢性鼻竇炎併鼻息肉、慢性自發性蕁麻疹 |
| 預測新適應症 | bronchitis、atopic eczema、obstructive lung disease、allergic asthma、皮膚炎、intrinsic asthma、bronchial neoplasm (disease)、acne keloid、acrodermatitis chronica atrophicans、hydroa vacciniforme, familial |
| TxGNN 預測分數 | 99.99% (支氣管炎), 99.97% (異位性皮膚炎) |
| 證據等級 | L2 |
| 台灣上市 | 已上市 |
| 許可證數 | 2 張 |
| 建議決策 | Explore |
預測適應症詳細分析
1. bronchitis L2 100.00% 主要分析
為什麼這個預測合理？
Omalizumab 通過與游離 IgE 結合，阻止 IgE 與肥大細胞和嗜鹼性球上的高親和力受體（FcεRI）結合，從而抑制過敏性炎症反應。
</p>
</details>
此預測基於藥物的作用機轉，與現有臨床證據方向一致。
臨床試驗
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT02049294 | PHASE2, PHASE3 | COMPLETED | 11 | Randomized Double Blind Placebo Controlled Trial of the Steroid Sparing Effect o... |
| NCT02477332 | PHASE2 | COMPLETED | 382 | A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2... |
相關文獻
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 16222080 | 2005 | Article | Clinical reviews in allergy & | Omalizumab in asthma: approval and postapproval experience. |
| 21121874 | 2011 | Article | Current medical research and o | Safety and tolerability of omalizumab in children with allergic (IgE-mediated) a... |
| 30196731 | 2018 | Article | Expert opinion on pharmacother | Challenges in the management of asthma associated with smoking-induced airway di... |
| 35369622 | 2022 | Article | Postepy dermatologii i alergol | Omalizumab in middle-aged or older patients with severe allergic asthma-COPD ove... |
| 17663923 | 2007 | Article | Allergologia et immunopatholog | Monoclonal antibodies in pediatrics: use in prevention and treatment. |
| 21163396 | 2010 | Article | Revue des maladies respiratoir | [Adult asthma exacerbations in questions]. |
| 31478531 | 2019 | Article | Journal of investigational all | A Rare Case of Plastic Bronchitis Following Bronchial Thermoplasty. |
| 26466493 | 2015 | Article | Masui. The Japanese journal of | [Preoperative Management of Patients with Bronchial Asthma or Chronic Bronchitis... |
2. atopic eczema L1 99.97%
臨床試驗（18 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT04037176 | PHASE4 | COMPLETED | 20 | Treatment With Omalizumab in Food Allergic Children (TOFAC) |
| NCT05564221 | PHASE1 | COMPLETED | 46 | A Randomized, Double-Blind, Placebo/Active Controlled, Multiple Ascending Dose, ... |
| NCT04060550 | N/A | UNKNOWN | 36 | Investigate the Impact of Increased IgE on Innate Anti-herpes Simplex Virus 1 Re... |
| NCT05674695 | N/A | RECRUITING | 2500 | Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis The... |
| NCT01179529 | PHASE2 | COMPLETED | N/A | Single- Arm Trial to Identify Potential Markers Underlying Variability in Respon... |
| NCT00367016 | PHASE4 | COMPLETED | 6 | Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) |
| NCT02300701 | PHASE4 | COMPLETED | 62 | The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paedi... |
| NCT01678092 | PHASE1 | COMPLETED | 8 | Phase 1, Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis |
| NCT04535817 | PHASE1 | WITHDRAWN | 0 | The Effect of Omalizumab (Xolair) on Improving Neuropsychiatric Symptoms in a Su... |
| NCT01544348 | PHASE1 | COMPLETED | 295 | A Phase 1 Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the ... |
| NCT00822783 | PHASE4 | COMPLETED | N/A | An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanist... |
| NCT03964051 | PHASE4 | TERMINATED | 7 | Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific... |
| NCT00123630 | PHASE2 | COMPLETED | 30 | A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab |
| NCT04763447 | PHASE4 | RECRUITING | 234 | Impact of Omalizumab Withdrawal After a 3 Year Duration Treatment in Well Contro... |
| NCT01995747 | N/A | COMPLETED | 52 | The Effect of Humanized Anti-CεmX Antibody (h4B12) on IgE Production in the PBMC... |
| NCT04680117 | NA | UNKNOWN | 150 | Defining the Severe Paediatric Asthma Endotype: an Integrated Approach Combining... |
| NCT05031455 | PHASE2 | RECRUITING | 16 | Mechanisms of Dupilumab in AERD - Effects on Aspirin Hypersensitivity Response, ... |
| NCT07021495 | N/A | RECRUITING | 840 | A Prospective, Multi-Center, Observational Biomarker Real-World Evidence Study f... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 35980214 | 2022 | Article | Journal of the European Academ | European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. |
| 36878860 | 2023 | Article | International forum of allergy | International consensus statement on allergy and rhinology: Allergic rhinitis - ... |
| 36411004 | 2023 | Article | Immunology and allergy clinics | Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Derm... |
| 39600395 | 2024 | Article | Allergologie select | Biologics in allergology and clinical immunology: Update on therapies for atopic... |
| 38812522 | 2024 | Article | Frontiers in immunology | Effectiveness and safety of systemic therapy for moderate-to-severe atopic derma... |
| 36355314 | 2023 | Article | Dermatology and therapy | The Combination of Dupilumab with Other Monoclonal Antibodies. |
| 29438602 | 2018 | Article | International forum of allergy | International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. |
| 31764954 | 2020 | Article | JAMA pediatrics | Omalizumab for Atopic Dermatitis: Overtreatment or Lifesaver? |
| 30717578 | 2019 | Article | Giornale italiano di dermatolo | Omalizumab for atopic dermatitis: evidence for and against its use. |
| 33710614 | 2021 | Article | The Cochrane database of syste | Biologics for chronic rhinosinusitis. |
| 35987486 | 2022 | Article | The journal of allergy and cli | Safety of Biologics for Atopic Diseases During Pregnancy. |
| 38488239 | 2024 | Article | Otolaryngology--head and neck | Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review. |
| 39158477 | 2024 | Article | Immunological reviews | Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarm... |
| 37854067 | 2023 | Article | Allergologie select | Diagnosis and treatment of Hymenoptera venom allergy: S2k Guideline of the Germa... |
| 40097336 | 2025 | Article | International journal of derma | Evidence-Based Recommendations for Managing Atopic Dermatitis in Pediatric Patie... |
| 38908432 | 2024 | Article | Annals of allergy, asthma & im | Atopic dermatitis and IgE-mediated food allergy: Common biologic targets for the... |
| 27759482 | 2017 | Article | The Journal of dermatological | Dermatologic uses of omalizumabtitle. |
| 33074565 | 2021 | Article | Allergy | Systemic treatments in the management of atopic dermatitis: A systematic review ... |
| 33310179 | 2021 | Article | Annals of allergy, asthma & im | Traditional Chinese medicine for food allergy and eczema. |
| 39413330 | 2024 | Article | Cutis | Does Omalizumab Cause Atopic Dermatitis Flare-Ups? |
3. obstructive lung disease L1 99.97%
臨床試驗（50 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT00624832 | PHASE4 | COMPLETED | 60 | A Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy... |
| NCT00286416 | NA | UNKNOWN | 60 | Double Blind Study to Determine Effect of Omalizumab Treatment in Patients With ... |
| NCT00870584 | PHASE4 | COMPLETED | 271 | A 26-week Randomized, Double-blind, Placebo-controlled, Multi-center Study to Ev... |
| NCT04998604 | PHASE4 | COMPLETED | 360 | A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizum... |
| NCT01584687 | PHASE4 | UNKNOWN | 6 | mRNA Expression as a Biomarker of Xolair (Omalizumab) Response |
| NCT00189228 | NA | COMPLETED | 18 | Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Ce... |
| NCT00208234 | PHASE4 | UNKNOWN | 22 | The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness |
| NCT00133042 | PHASE4 | COMPLETED | 16 | The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With ... |
| NCT05270278 | N/A | COMPLETED | 89 | Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomar... |
| NCT06261567 | N/A | COMPLETED | 415 | A Retrospective Chart Review to Investigate Clinical Remission in Patients With ... |
| NCT00314574 | PHASE3 | COMPLETED | 850 | A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ... |
| NCT00777764 | PHASE4 | COMPLETED | 60 | The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Oma... |
| NCT00482248 | PHASE3 | COMPLETED | 132 | An Open-label Extension Study to Assess Long Term Safety and Tolerability of Oma... |
| NCT00377390 | N/A | COMPLETED | 224 | Inner-City Anti-IgE Therapy for Asthma Mechanistic Study |
| NCT05157087 | N/A | COMPLETED | 16246 | XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United... |
| NCT00079937 | PHASE3 | COMPLETED | 628 | A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicen... |
| NCT00401596 | PHASE3 | COMPLETED | 1899 | A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety o... |
| NCT01397760 | N/A | UNKNOWN | 20 | Retrospective Study for Description of The Use Of Omalizumab In Patients With Di... |
| NCT00232050 | PHASE3 | COMPLETED | 327 | Study of Omalizumab in Moderate to Severe Bronchial Asthma |
| NCT00670930 | PHASE4 | COMPLETED | 36 | A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Tri... |
| NCT00329381 | PHASE4 | COMPLETED | 14 | A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered St... |
| NCT03727971 | PHASE2 | COMPLETED | 66 | Use of Omalizumab Will Increase the Pregnancy Rate, Proof of Concept Study, Wher... |
| NCT05792592 | N/A | UNKNOWN | 54 | Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Ta... |
| NCT00639691 | PHASE4 | COMPLETED | 48 | A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab)in ... |
| NCT06869382 | PHASE4 | COMPLETED | 26 | Comparative Analysis of ICS Combined with LABA Versus Addition of Omalizumab on ... |
| NCT01202903 | PHASE3 | COMPLETED | 616 | A 24-week, Phase III Randomized, Double-blind, Placebocontrolled, Parallel-group... |
| NCT00046748 | PHASE3 | COMPLETED | 484 | Ph III, 28-wk, Multicenter, Randomized, Double-blind, Placebo-controlled, Parall... |
| NCT00180011 | PHASE2, PHASE3 | COMPLETED | 18 | Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to ... |
| NCT01976208 | PHASE2, PHASE3 | COMPLETED | 630 | A Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Study to ... |
| NCT00546143 | PHASE4 | COMPLETED | 32 | Multi-center, Open-label, Multiple Dose Study in Mild to Moderate Asthmatics (Wi... |
| NCT06456450 | N/A | RECRUITING | 500 | Taiwan Severe Asthma Biologic Registry |
| NCT01430403 | PHASE4 | COMPLETED | 478 | Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (ICAC-2... |
| NCT06024707 | N/A | UNKNOWN | 48 | Early Detection of the Effectiveness of Treatment With Biologicals in Patients W... |
| NCT01219036 | NA | COMPLETED | 40 | The Use of Fractional Exhaled Nitric Oxide (FeNO) and Induced Sputum in the Iden... |
| NCT00434434 | PHASE2 | COMPLETED | 61 | A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Contr... |
| NCT00109187 | PHASE3 | COMPLETED | 0 | Open-Label Extension Study II of Xolair (Omalizumab) in Moderate to Severe, Pers... |
| NCT00367016 | PHASE4 | COMPLETED | 6 | Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) |
| NCT00567476 | PHASE4 | COMPLETED | 116 | A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Om... |
| NCT04607629 | PHASE3 | COMPLETED | 192 | A Comparative Study of Efficacy and Safety of Genolar® and Xolar® in Treating Pa... |
| NCT00784485 | PHASE4 | TERMINATED | 13 | Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Trea... |
| NCT02293265 | PHASE3 | COMPLETED | 767 | Identification and Description of Severe Asthma Patients in a Cross-sectional St... |
| NCT00219323 | PHASE3 | COMPLETED | 133 | Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma |
| NCT03476109 | PHASE4 | UNKNOWN | 100 | Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Al... |
| NCT00813748 | N/A | COMPLETED | 118 | Pharmacosurveillance Data Repository of Patients With and Without History of Ana... |
| NCT00096954 | PHASE4 | COMPLETED | 333 | A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xol... |
| NCT05001529 | PHASE4 | UNKNOWN | 80 | Flow Cytometry Analysis of Eosinophils Activity and Membrane Receptors Expressio... |
| NCT01449409 | NA | ACTIVE_NOT_RECRUITING | 3000 | Reduce IDentified UNcontrolled Asthma: A Real-time Randomized Administrative Out... |
| NCT01393340 | PHASE2 | COMPLETED | 23 | Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilate... |
| NCT00495612 | PHASE4 | COMPLETED | 69 | A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Study o... |
| NCT01460862 | N/A | WITHDRAWN | 0 | Analyze the Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits an... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 36740144 | 2023 | Article | The Journal of allergy and cli | Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A... |
| 37869947 | 2023 | Article | European review for medical an | Biologics in allergic rhinitis. |
| 36581073 | 2023 | Article | The journal of allergy and cli | Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and M... |
| 39186985 | 2024 | Article | The Journal of allergy and cli | Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations an... |
| 41033334 | 2025 | Article | The Lancet. Respiratory medici | Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal p... |
| 11496232 | 2001 | Article | The Journal of allergy and cli | Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatmen... |
| 31760132 | 2020 | Article | Annals of allergy, asthma & im | Effect of omalizumab on lung function and eosinophil levels in adolescents with ... |
| 11270941 | 2001 | Article | Drugs | Omalizumab. |
| 25404353 | 2014 | Article | Paediatric drugs | Omalizumab in children. |
| 26075226 | 2015 | Article | BioMed research international | Advances in anti-IgE therapy. |
| 38235607 | 2024 | Article | Therapeutic advances in respir | Effects of omalizumab on lung function in patients with moderate-to-severe aller... |
| 33160970 | 2021 | Article | The Journal of allergy and cli | Omalizumab in "non-IgE-mediated" diseases. |
| 22264640 | 2012 | Article | Allergologia et immunopatholog | Omalizumab beyond asthma. |
| 31145939 | 2020 | Article | The Journal of allergy and cli | Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched co... |
| 27824606 | 2016 | Article | The European respiratory journ | Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopi... |
| 24477463 | 2014 | Article | Pneumologie (Stuttgart, German | [Disease modification and duration of omalizumab treatment in patients with seve... |
| 38474304 | 2024 | Article | International journal of molec | The Incredible Adventure of Omalizumab. |
| 26772933 | 2016 | Article | The journal of allergy and cli | Omalizumab and Allergic Reactions. |
| 34384308 | 2023 | Article | Journal of pharmacy practice | Effectiveness and Safety Studies of Omalizumab in Children and Adolescents With ... |
| 28189435 | 2017 | Article | Revue des maladies respiratoir | [Omalizumab: Beyond anti-IgE properties]. |
4. dermatitis L1 99.97%
臨床試驗（19 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT04037176 | PHASE4 | COMPLETED | 20 | Treatment With Omalizumab in Food Allergic Children (TOFAC) |
| NCT05564221 | PHASE1 | COMPLETED | 46 | A Randomized, Double-Blind, Placebo/Active Controlled, Multiple Ascending Dose, ... |
| NCT04060550 | N/A | UNKNOWN | 36 | Investigate the Impact of Increased IgE on Innate Anti-herpes Simplex Virus 1 Re... |
| NCT05674695 | N/A | RECRUITING | 2500 | Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis The... |
| NCT01179529 | PHASE2 | COMPLETED | N/A | Single- Arm Trial to Identify Potential Markers Underlying Variability in Respon... |
| NCT00367016 | PHASE4 | COMPLETED | 6 | Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) |
| NCT02300701 | PHASE4 | COMPLETED | 62 | The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paedi... |
| NCT01678092 | PHASE1 | COMPLETED | 8 | Phase 1, Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis |
| NCT04535817 | PHASE1 | WITHDRAWN | 0 | The Effect of Omalizumab (Xolair) on Improving Neuropsychiatric Symptoms in a Su... |
| NCT01544348 | PHASE1 | COMPLETED | 295 | A Phase 1 Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the ... |
| NCT00822783 | PHASE4 | COMPLETED | N/A | An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanist... |
| NCT03964051 | PHASE4 | TERMINATED | 7 | Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific... |
| NCT00123630 | PHASE2 | COMPLETED | 30 | A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab |
| NCT04763447 | PHASE4 | RECRUITING | 234 | Impact of Omalizumab Withdrawal After a 3 Year Duration Treatment in Well Contro... |
| NCT01995747 | N/A | COMPLETED | 52 | The Effect of Humanized Anti-CεmX Antibody (h4B12) on IgE Production in the PBMC... |
| NCT04680117 | NA | UNKNOWN | 150 | Defining the Severe Paediatric Asthma Endotype: an Integrated Approach Combining... |
| NCT05031455 | PHASE2 | RECRUITING | 16 | Mechanisms of Dupilumab in AERD - Effects on Aspirin Hypersensitivity Response, ... |
| NCT07021495 | N/A | RECRUITING | 840 | A Prospective, Multi-Center, Observational Biomarker Real-World Evidence Study f... |
| NCT00260702 | PHASE1 | COMPLETED | 1 | Pilot Study of Omalizumab (Xolair) in Hyper IgE (Job's) Syndrome |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 30717578 | 2019 | Article | Giornale italiano di dermatolo | Omalizumab for atopic dermatitis: evidence for and against its use. |
| 27337170 | 2017 | Article | International journal of derma | Omalizumab for atopic dermatitis: case series and a systematic review of the lit... |
| 36878860 | 2023 | Article | International forum of allergy | International consensus statement on allergy and rhinology: Allergic rhinitis - ... |
| 36411004 | 2023 | Article | Immunology and allergy clinics | Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Derm... |
| 35980214 | 2022 | Article | Journal of the European Academ | European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. |
| 37988298 | 2023 | Article | Cutis | Atopic Dermatitis Triggered by Omalizumab and Treated With Dupilumab. |
| 38812522 | 2024 | Article | Frontiers in immunology | Effectiveness and safety of systemic therapy for moderate-to-severe atopic derma... |
| 27543070 | 2016 | Article | The Journal of allergy and cli | Efficacy of omalizumab in patients with atopic dermatitis: A systematic review a... |
| 31998003 | 2019 | Article | Postepy dermatologii i alergol | Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-Eas... |
| 31764954 | 2020 | Article | JAMA pediatrics | Omalizumab for Atopic Dermatitis: Overtreatment or Lifesaver? |
| 29438602 | 2018 | Article | International forum of allergy | International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. |
| 31233174 | 2019 | Article | Acta dermatovenerologica Alpin | Lack of omalizumab efficacy in severe atopic dermatitis with extremely elevated ... |
| 33710614 | 2021 | Article | The Cochrane database of syste | Biologics for chronic rhinosinusitis. |
| 39158477 | 2024 | Article | Immunological reviews | Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarm... |
| 36355314 | 2023 | Article | Dermatology and therapy | The Combination of Dupilumab with Other Monoclonal Antibodies. |
| 34273058 | 2021 | Article | Clinical reviews in allergy & | Current Perspectives on Severe Drug Eruption. |
| 38488239 | 2024 | Article | Otolaryngology--head and neck | Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review. |
| 35987486 | 2022 | Article | The journal of allergy and cli | Safety of Biologics for Atopic Diseases During Pregnancy. |
| 40097336 | 2025 | Article | International journal of derma | Evidence-Based Recommendations for Managing Atopic Dermatitis in Pediatric Patie... |
| 33074565 | 2021 | Article | Allergy | Systemic treatments in the management of atopic dermatitis: A systematic review ... |
5. bronchial neoplasm (disease) L2 99.95%
臨床試驗（2 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT06869382 | PHASE4 | COMPLETED | 26 | Comparative Analysis of ICS Combined with LABA Versus Addition of Omalizumab on ... |
| NCT04680117 | NA | UNKNOWN | 150 | Defining the Severe Paediatric Asthma Endotype: an Integrated Approach Combining... |
相關文獻（1 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 20955114 | 2010 | Article | Expert opinion on biological t | Omalizumab for pediatric asthma. |
6. acne keloid L5 99.94%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
7. acrodermatitis chronica atrophicans L5 99.93%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
8. hydroa vacciniforme, familial L5 99.93%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
9. neonatal dermatomyositis L5 99.93%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
10. secondary interstitial lung disease specific to childhood associated with a connective tissue disease L5 99.92%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
資料來源：DDInter 2.0（原文內容請參閱該網站）
**Neoplasms** 🟡 Moderate
- 應謹慎使用本藥物。
## 結論與下一步
**決策：Explore**
**理由：**
Omalizumab 對異位性皮膚炎和支氣管炎的預測具有合理的藥理學基礎，且有多項臨床試驗探索這些應用。異位性皮膚炎的試驗結果顯示部分患者受益，但療效不一致，可能與 IgE 水平和其他因素有關。支氣管炎（特別是嗜酸性球性支氣管炎）與過敏性氣喘有重疊機制，使用 omalizumab 具有合理性。
然而，需注意：
- Dupilumab 已成為異位性皮膚炎的標準生物製劑治療
- 支氣管炎病因多樣，非所有類型都適合抗 IgE 治療
**若要推進需要：**
- 明確哪些亞群患者最可能從 omalizumab 受益
- 與現有標準治療（如 dupilumab for AD）的比較研究
- 開發預測治療反應的生物標記
- 評估高 IgE 水平患者（>700 IU/mL）的劑量策略
---
## 相關藥物報告
- [Hydroxyurea](/drugs/hydroxyurea/) - 證據等級 L2
- [Oteracil](/drugs/oteracil/) - 證據等級 L2
- [Isosorbide Dinitrate](/drugs/isosorbide_dinitrate/) - 證據等級 L2
- [Gemcitabine](/drugs/gemcitabine/) - 證據等級 L2
- [Carboplatin](/drugs/carboplatin/) - 證據等級 L2
---
用 AI 幫我深入分析
想進一步了解這個藥物的老藥新用潛力嗎？點擊下方按鈕，直接開啟 AI 助手進行分析。
Claude：點擊後會複製提問並開啟新視窗，請按 Ctrl+V（Mac: Cmd+V）貼上
ChatGPT：點擊後直接開啟並自動帶入提問
免責聲明
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
歡迎分享您對本報告的看法、補充資訊或提出問題。討論內容會同步到 GitHub Discussions。 需要 GitHub 帳號才能留言。